SBIR/STTR Research Award

EXPRESSION OF ENZYMES AND INHIBITORS OF METASTASIS

Award identifier 9c6dc2ff3e13969bb535f02d24f1bdf3d316df56981ab659294133ba90a7ad16Awarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1992

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Molecular Oncology Inc
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DEGRADATION OF COLLAGEN IV IN BASEMENT MEMBRANES HAS BEEN IMPLICATED IN THE PATHOGENESIS OF METASTASIS, AND IN THE PROCESS OF ANGIOGENESIS. THE 72 KD AND THE 92 KD TYPE IV COLLAGENASES ARE METALLOPROTEASES CAPABLE OF DEGRADING COLLAGEN IV WHICH HAVE BEEN SUGGESTED TO PLAY A CRITICAL ROLE IN THE ABILITY OF CELLS TO PENETRATE BASEMENT MEMBRANES. A NATURALLY OCCURRING INHIBITOR OF METALLOPROTEASES, TIMP-2 (TISSUE INHIBITOR OF METALLOPROTEASE-2), FORMS A NONCOVALENT COMPLEX WITH THE 72 KD ENZYME AND INHIBITS ITS ACTIVITY AND THE ACTIVITY OF THE 92 KD ENZYME. TO INVESTIGATE THE BIOCHEMICAL AND BIOLOGICAL PROPERTIES OF THESE PROTEINS AND TO TEST THEIR EFFICACY FOR THE DIAGNOSTIC AND TREATMENT OF METASTASIS AND ANGIOGENIC DISEASES WE INTEND TO EXPRESS ANALYTICAL AMOUNTS OF TIMP-2 AND TYPE IV COLLAGENASES IN MAMMALIAN CELLS USING A RECOMBINANT VACCINIA VIRUS EXPRESSION SYSTEM (VAC/T7). SINCE ACTIVE TYPE IV COLLAGENASES CANNOT BE ISOLATED FROM NATIVE ENZYME-INHIBITOR COMPLEXES, PRODUCTION OF THESE PROTEINS IN THE VAC/T7 SYSTEM AS SINGLE POLYPEPTIDES WILL PROVIDE THE REAGENTS TO CHARACTERIZE THEIR BIOCHEMICAL PROPERTIES, BINDING SITES, AND INHIBITORY ACTIVITY. ALSO, THE RECOMBINANT PROTEINS WILL BE VALUABLE FOR THE CHARACTERIZATION OF MONOCLONAL ANTIBODIES. THE ABILITY TO DETECT AND TO INHIBIT TYPE IV COLLAGENASE ACTIVITY WILL BE IMPORTANT FOR THE TREATMENT AND DIAGNOSIS OF MALIGNANT DISEASE.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.